Frost Sullivan Presents Protalix Biotherapeutics with its 2009 European Orphan Diseases Market Product Innovation of the Year Award

Frost Sullivan Presents Protalix Biotherapeutics with its 2009 European Orphan

Diseases Market Product Innovation of the Year Award

CARMIEL, Israel, June 4, 2009 (Business Wire) Protalix BioTherapeutics, Inc. (NYSE-AMEX:PLX),

announced today that Frost Sullivan has presented the Company with its 2009 European Orphan

Diseases Market Product Innovation of the Year Award. In presenting the award, Frost Sullivan

noted the Company s impressive display of technology and innovative efforts in developing prGCD,

the Company s proprietary plant cell expressed recombinant form of human Glucocerebrosidase (GCD)

for the treatment of Gaucher disease using its proprietary expression system, ProCellEx .

Frost Sullivan bestows the European Orphan Diseases Market Product Innovation Award on a company

or individual that has performed new research which has resulted in technological innovation(s)

that have brought, or are expected to bring, significant contributions to the industry in terms of

adoption, change, and competitive posture. The award recognizes the quality and depth of the

recipient s research and development program as well as the vision and risk-taking that enabled the

recipient to undertake the research for which the recipient is being recognized.

In granting this award to Protalix, Frost Sullivan noted that ProCellEx, the Company s

proprietary expression system used to produce prGCD, has the potential to enhance drug properties

such as better efficacy, longer half-life, cost effectiveness and better patient compliance.

According to Frost Sullivan, the Company s product candidates are expected to be cost effective

when compared to existing therapies because they are produced using, a plant cell culture-based

expression system. Existing enzyme replacement therapies are produced using mammalian cell-based

expression systems, a production method that is expensive and results in increased production

Frost Sullivan further stated that through the development of prGCD using the ProCellEx

production system, Protalix Biotherapeutics has developed a product with capabilities and

characteristics that positively differentiate it from the enzyme replacement therapies available in

the market. The current global market of Gaucher disease is estimated around $1.30 billion and

there is only one enzyme replacement therapy currently available. By positioning its focus on a

high profile and underserved area of orphan diseases, Protalix Biotherapeutics has moved to become

a recognized name for product innovation in the area.

Receiving this award from Frost Sullivan provides further validation of our innovative approach

to manufacturing proteins in a plant cell-based expression system, said Dr. David Aviezer, the

Company s President and Chief Executive Officer. We have completed patient enrollment in our

pivotal Phase III clinical trial of prGCD for the treatment of Gaucher disease, and the trial s

design was the product of an agreement with the FDA under its special protocol assessment process.

We look forward to reporting the results of this trial in the fourth quarter of 2009.

About Frost and Sullivan

Frost Sullivan, the Growth Consulting Company, partners with clients to accelerate their growth.

The company s Growth Partnership Services, Growth Consulting and Career Best Practices empower

clients to create a growth focused culture that generates, evaluates and

implements effective growth strategies. Frost Sullivan employs over 45 years of experience in

partnering with Global 1000 companies, emerging businesses and the investment community from more

than 30 offices on six continents. For more information about Frost Sullivan s Growth

Partnerships, visit http://www.frost.com.

About Protalix BioTherapeutics

Protalix is a biopharmaceutical company. Its goal is to become a fully integrated

biopharmaceutical company focused on the development and commercialization of proprietary

recombinant therapeutic proteins to be expressed through its proprietary plant cell based

expression system. Protalix s ProCellEx(TM) presents a proprietary method for the expression of

recombinant proteins that Protalix believes will allow for the cost-effective, industrial-scale

production of recombinant therapeutic proteins. Protalix is conducting a phase III pivotal study

for its lead product candidate, prGCD, to be used in enzyme replacement therapy for Gaucher

disease, a lysosomal storage disorder in humans. Protalix has reached an agreement with the United

States Food and Drug Administration on the final design of the pivotal phase III clinical trial

through the FDA s Special Protocol Assessment (SPA) process. Protalix has completed enrollment for

this study and is treating patients in its pivotal phase III clinical trial in North America, South

America, Israel, Europe and South Africa. The study is monitored by an independent Data Monitoring

Committee including experts in the field, who monitor the on going safety data, which has recently

held their last scheduled meeting before the end of the trial. No serious adverse events have been

reported in the study. Protalix is also advancing additional recombinant biopharmaceutical drug

development programs.

The Trout Group, LLC

Telephone: 646-378-2927

Email: mnanus@troutgroup.com